Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702107 | 0.86 | KIF11 (0.42) | AXLKIF11TRPA1ALDH1A1TDP1 | |
| SCHEMBL6905689 | 0.81 | AXL (0.33) | AXLKIF11 | |
| SCHEMBL28473114 | 0.79 | KIF11 (0.33) | AXLKIF11 | |
| SCHEMBL15519432 | 0.78 | — | — | |
| SCHEMBL28994959 | 0.78 | KIF11 (0.33) | KIF11 | |
| SCHEMBL30027744 | 0.78 | KIF11 (0.36) | KIF11TRPA1ALDH1A1GRM4 | |
| SCHEMBL31668752 | 0.77 | KIF11 (0.31) | AXLKIF11 | |
| SCHEMBL28360108 | 0.75 | TRPA1 (0.42) | AXLKIF11HSD11B1TRPA1TRPM8 | |
| SCHEMBL17150367 | 0.75 | PARP1 (0.58) | AXLKIF11PARP1NOTUML3MBTL1 | |
| SCHEMBL28320385 | 0.75 | KIF11 (0.31) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115667580-A | Conductive particle, conductive material using same, and connection structure | 日本化学工业株式会社 | 2023-01-31 | — | — | CN | disclosed |
| CN-115667579-A | Method for producing conductive particles and conductive particles | 日本化学工业株式会社 | 2023-01-31 | — | — | CN | disclosed |
| CN-112384994-B | Coated particles | 日本化学工业株式会社 | 2022-10-04 | — | — | CN | disclosed |
| CN-113270631-A | Electrolyte for high energy density graphite-containing batteries | 通用汽车环球科技运作有限责任公司 | 2021-08-17 | — | — | CN | disclosed |
| US-10947263-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200223883-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2020-07-16 | — | — | US | disclosed |
| WO-2019046498-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-2941419-A1 | UV-ABSORBERS FOR OPHTHALMIC LENS MATERIALS | Novartis AG (CH) | 2015-11-11 | — | — | EP | disclosed |
| WO-2015072991-A1 | UV-ABSORBERS FOR OPHTHALMIC LENS MATERIALS | NOVARTIS AG (CH) | 2015-05-21 | — | — | WO | disclosed |
| US-8585938-B1 | UV-absorbers for ophthalmic lens materials | NOVARTIS AG (CH) | 2013-11-19 | — | — | US | disclosed |
| EP-0971049-A1 | Methods of inhibiting corrosion using halo-benzotriazoles | BetzDearborn Inc (US) | 2000-01-12 | — | — | EP | disclosed |
| US-5863463-A | Methods of inhibiting corrosion using halo-benzotriazoles | BETZDEARBORN INC. (US) | 1999-01-26 | — | — | US | disclosed |
| US-5863464-A | ADDING TO AN AQUEOUS SYSTEM TREATED WITH HALOGEN AN EFFECTIVE AMOUNT OF MONO OR DI-HALOBENZOTRIAZOLE CORROSION INHIBITOR OR ANTIDEPOSIT AGENT | BETZDEARBORN INC. (US) | 1999-01-26 | — | — | US | disclosed |
| US-5772919-A | CORROSION RESISTANCE OF METALS IN AQUEOUS SYSTEMS AND WITH HALOGEN TREATMENT | BETZDEARBORN INC. (US) | 1998-06-30 | — | — | US | disclosed |
| US-5773627-A | MIXING SODIUM HYPOHALITE WITH AQUEOUS SLURRY OR SUSPENSION OF A BENZOTRIAZOLE | BETZDEARBORN INC. (US) | 1998-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947263-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | AXL 4481/4885KIF11 3568/4885PARP1 21/4885 |
| US-20200223883-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | AXL 4481/4885KIF11 3568/4885PARP1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.